161 related articles for article (PubMed ID: 12752488)
1. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.
Barnett AH; Grant PJ; Hitman GA; Mather H; Pawa M; Robertson L; Trelfa A;
Diabet Med; 2003 May; 20(5):387-93. PubMed ID: 12752488
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
[TBL] [Abstract][Full Text] [Related]
3. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
[TBL] [Abstract][Full Text] [Related]
4. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
Fonseca V; Rosenstock J; Patwardhan R; Salzman A
JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
Nolan JJ; Jones NP; Patwardhan R; Deacon LF
Diabet Med; 2000 Apr; 17(4):287-94. PubMed ID: 10821295
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
Patel J; Anderson RJ; Rappaport EB
Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
[TBL] [Abstract][Full Text] [Related]
7. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.
Rosenstock J; Rood J; Cobitz A; Huang C; Garber A
Diabetes Obes Metab; 2006 Nov; 8(6):643-9. PubMed ID: 17026488
[TBL] [Abstract][Full Text] [Related]
8. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
[TBL] [Abstract][Full Text] [Related]
9. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
[TBL] [Abstract][Full Text] [Related]
10. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?
Goldstein BJ; Cobitz AR; Hand LM; Chen H
Curr Med Res Opin; 2003; 19(3):192-9. PubMed ID: 12803733
[TBL] [Abstract][Full Text] [Related]
11. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
Zhu XX; Pan CY; Li GW; Shi HL; Tian H; Yang WY; Jiang J; Sun XC; Davies C; Chow WH
Diabetes Technol Ther; 2003; 5(1):33-42. PubMed ID: 12725705
[TBL] [Abstract][Full Text] [Related]
12. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.
Jones TA; Sautter M; Van Gaal LF; Jones NP
Diabetes Obes Metab; 2003 May; 5(3):163-70. PubMed ID: 12681023
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
14. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
Raskin P; Rappaport EB; Cole ST; Yan Y; Patwardhan R; Freed MI
Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes.
Gómez-Perez FJ; Fanghänel-Salmón G; Antonio Barbosa J; Montes-Villarreal J; Berry RA; Warsi G; Gould EM
Diabetes Metab Res Rev; 2002; 18(2):127-34. PubMed ID: 11994904
[TBL] [Abstract][Full Text] [Related]
17. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M; Shaw J; Brändle M; Bebakar WM; Kamaruddin NA; Strand J; Zdravkovic M; Le Thi TD; Colagiuri S;
Diabet Med; 2009 Mar; 26(3):268-78. PubMed ID: 19317822
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.
Wagstaff AJ; Goa KL
Drugs; 2002; 62(12):1805-37. PubMed ID: 12149047
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]